Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
SYDNEY, April 01, 2026 (GLOBE NEWSWIRE) -- Actinogen Medical Limited (ASX: ACW) announces that the first participant has been treated in the open-label extension (OLE) phase of the XanaMIA trial...
-
TORONTO, March 31, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory...
-
Inhibitor Therapeutics (OTCQB: INTI) updates itraconazole PK study, highlights amorphous formulation and planned global patent filing.
-
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral...
-
Name chosen for AVERSA Fentanyl commercial product
-
AEON Biopharma Reports Full Year 2025 Financial Results and Highlights Positive Comparative Analytical Results and FDA Feedback for ABP-450 Biosimilar Prog
-
Cathie Wood and ARK Invest are making a decisive pivot that signals where the next phase of AI value creation may emerge: healthcare
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
Thera Liechtenstein brings extensive biotech investment and company‑building experience to new role as Partner at 4BIO CapitalTetsu Maruyama, former Head of Drug Discovery at Takeda Pharmaceuticals,...
-
Envudeucitinib late-breaking data at AAD: early and robust improvements in skin clearance, quality of life and psoriasis symptoms in two Phase 3 trials